NASDAQ$TTOO

T2 Biosystems Inc · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Briefing

Announced second quarter 2020 financial results, highlighted by a revenue increase and the launch of the T2SARS-CoV-2 Panel.

T2 Biosystems reported a 41% increase in total revenue for the second quarter of 2020, driven by a significant rise in research and contribution revenue. The company also launched its T2SARS-CoV-2 Panel and strengthened its balance sheet through stock sales.

  • Total revenue increased by 41% to $2.6 million compared to the prior year period.
  • Product revenue decreased by 18% to $1.0 million due to lower instrument sales internationally.
  • Research and contribution revenue increased by 185% to $1.5 million, driven by increased U.S. government contract funding.
  • Net loss decreased to $10.7 million, or $0.09 per share, compared to $15.6 million, or $0.35 per share, in the prior year period.

Headline financials

Total Revenue

$2.55M

Previous: $1.8M+41.5%
EPS (adj)

-$450.00

No prior period
Capital Expenditures

-$127K

Previous: -$444K+71.4%
Free Cash Flow

-$28.4M

Previous: -$22.2M-28.0%
Net Income

-$10.7M

Previous: -$15.6M+31.7%
Operating Income

-$8.84M

Previous: -$13.8M+35.9%
Gross Profit

-$636K

Previous: -$173K-267.6%
Cash & Equivalents

$26.5M

Previous: $28.4M-6.6%
Total Assets

$53.7M

Previous: $45.2M+18.9%

Revenue & EPS history

T2 Biosystems · Revenue · Quarterly

$2.55M

Q2 2020+41.5%vs Q2 2019
Beat estimate in 9 of 16 quarters(56%)
ActualEstimate

Revenue by segment

T2 Biosystems · $1.04M total across 1 segment · Q2 2020

  • Product Revenue
    $1.04M-18.3%

Forward guidance

T2 Biosystems reissued its full-year 2020 revenue guidance, expecting total revenues between $18.0 million and $20.0 million, including product revenues between $13.0 million and $14.0 million and research and contribution revenues between $5.0 million and $6.0 million.

Tailwinds

  • Full year 2020 total revenues expected between $18.0 million to $20.0 million.
  • Product revenues expected between $13.0 million to $14.0 million.
  • Research and contribution revenues expected between $5.0 million to $6.0 million.
  • Expect to receive 60 T2Dx Instrument sales contracts in the U.S. in 2020.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2020

Historical avgQ2 2020

-6.3%

Avg return

Earnings day

-4.9%

Avg return

5 days after

-7.0%

Avg return

30 days after

32%

14 / 44 earnings

Positive

+24.0%

Q2 2023

Best reaction

-59.4%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025+0.8%-8.3%-8.3%
Q4 2024-1.4%-8.4%-12.0%
Q3 2024-9.3%-11.9%-33.4%
Q2 2024-3.9%-3.9%-34.0%
Q1 2024-12.9%-0.7%+24.7%
Q4 2023-1.3%-11.4%-32.9%
Q3 2023-5.4%-11.4%-15.7%
Q2 2023+24.0%+35.2%+20.4%
Q1 2023-59.4%-66.5%-73.9%
Q4 2022-0.2%-2.6%-24.7%
Q3 2022+8.0%+15.3%-15.9%
Q2 2022-16.1%-31.5%-39.5%
Q1 2022-22.9%-37.7%-51.0%
Q4 2021+0.9%-2.2%-2.7%
Q3 2021-3.1%-5.2%-35.2%
Q2 2021-13.2%-13.2%-23.8%
Q1 2021-5.6%-8.0%+0.8%
Q4 2020-21.2%+39.0%+5.5%
Q3 2020-3.0%-11.9%-14.8%
Q2 2020-24.3%-29.5%-37.6%
Q1 2020-9.6%-11.8%+103.1%
Q4 2019-19.2%+62.6%+37.1%
Q3 2019-37.4%-34.8%-57.0%
Q2 2019-59.3%-58.0%+3.4%
Q1 2019+12.8%+10.4%-22.0%
Q4 2018-19.6%-16.9%-15.6%
Q3 2018+11.2%-2.1%-15.4%
Q2 2018-5.5%+9.0%+15.2%
Q1 2018+11.5%+17.9%+36.5%
Q4 2017-2.7%-6.5%+6.1%
Q3 2017+9.2%+8.6%+7.3%
Q2 2017+13.7%+13.0%+66.0%
Q1 2017-16.2%-16.0%-21.5%
Q4 2016-3.4%+3.9%+3.6%
Q3 2016-8.7%-11.7%-13.6%
Q2 2016+8.0%+32.2%+17.3%
Q1 2016-0.9%
Q4 2015+0.7%
Q3 2015-0.4%
Q2 2015+4.5%
Q1 2015+5.2%
Q4 2014-0.6%
Q3 2014-7.9%
Q2 2014+5.0%
Q4 2013
Q3 2013
Q2 2013
Q1 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro